Frontiers in Oncology最新文献

{"title":"Does chemotherapy improve survival outcomes in breast cancer survivors with secondary primary stage I non-small cell lung cancer? A real-world analysis using machine learning models.","authors":"Bohao Liu, Lutong Yan, Jiaqi Huang, Xingzhuo Zhu, Jinteng Feng, Deqian Qiao, Na Hao, Guangjian Zhang, Shan Gao","doi":"10.3389/fonc.2025.1646580","DOIUrl":"10.3389/fonc.2025.1646580","url":null,"abstract":"<p><strong>Background: </strong>Advances in breast cancer treatment have prolonged survival, leading to an increased incidence of secondary primary lung cancer (SPLC) in survivors. This study aims to investigate the prognosis and treatment strategies for patients with recurrent early-stage lung cancer histories and establish predictive models to guide clinical practice.</p><p><strong>Methods: </strong>This study analyzed clinical data from 2,775 patients (2008-2024) extracted from the SEER database and 15 patients (2008-2024) from the cancer registry of the First Affiliated Hospital of Xi'an Jiaotong University. The analysis focused on comparing clinical characteristics, prognosis, and chemotherapy benefits between early-stage second primary lung cancer (SPLC) patients with a history of breast cancer and those with primary lung cancer. The average age of patients in the SEER cohort was 69.64 ± 8.89 years(31-90), while the 15 hospital-registered patients had an average age of 67.15 ± 9.12 years(43-77). We employed neural network-based machine learning methods to develop models for predicting treatment decisions. Specifically, the COX-lung and MLP-lung models were developed, with a LOG-lung model used for comparison.</p><p><strong>Results: </strong>LC patients with a prior breast cancer history had significantly poorer prognosis survival time of 93 months <i>vs</i> 129 months. Postoperative chemotherapy improved the prognosis for some patients; however, the population benefiting from chemotherapy exhibited specific clinical characteristics. The COX-lung and MLP-lung models accurately predicted chemotherapy beneficiaries, with the MLP-lung model achieving an AUC of 0.813 and high positive predictive value.</p><p><strong>Conclusion: </strong>SPLC with prior breast cancer do have a poorer prognosis than lung cancer patients, although postoperative chemotherapy can benefit some individuals, careful selection of patients to receive chemotherapy is still warranted. We developed COX-lung and MLP-lung models which can predict beneficiaries of chemotherapy, providing crucial insights for clinicians in formulating personalized treatment plans. The findings indicate that this patient population is heterogeneous, necessitating more individualized treatment strategies.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1646580"},"PeriodicalIF":3.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions.","authors":"Lu Wang, Weiwei Qiao, Xiaowen Zhen, Yeqiong Zhang, Zhiwei Dong","doi":"10.3389/fonc.2025.1646897","DOIUrl":"10.3389/fonc.2025.1646897","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA), a highly aggressive biliary tract malignancy, exhibits rising incidence rates and an extremely poor prognosis. Recent studies reveal that gut-liver axis dysregulation drives CCA progression through gut microbiota dysbiosis, bile acid (BA) metabolic disturbances, and immune microenvironment remodeling. Clinical evidence highlights significant alterations in the gut and biliary microbial composition of CCA patients, which correlate with tumor stage, vascular invasion, and survival outcomes. Dysregulated BA metabolism in CCA, characterized by accumulation of primary conjugated BAs, promotes tumor invasiveness via interaction with specific BA receptors and fosters an immunosuppressive microenvironment. Emerging therapeutic strategies include antibiotics for pathogenic microbiota modulation, probiotics for microbial homeostasis restoration, fecal microbiota transplantation, and BA pathway modulators. Future directions necessitate integrating synthetic biology (engineered microbiota), multi-omics, and artificial intelligence to develop precision therapies. Targeting the gut-liver axis offers novel therapeutic perspectives for CCA; however, clinical translation demands deeper mechanistic insights and standardized protocols to address challenges such as microbiota heterogeneity and receptor signaling duality.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1646897"},"PeriodicalIF":3.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: CS Ratio is an immune-related prognostic biomarker for cervical cancer.","authors":"Peiqin Shi, Wenwen Zhang, Qingqing Yao, Zhanna Yuan, Jiaqi Wang, Ziye Yang, Pengpeng Qu","doi":"10.3389/fonc.2025.1697346","DOIUrl":"https://doi.org/10.3389/fonc.2025.1697346","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fonc.2025.1547529.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1697346"},"PeriodicalIF":3.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary lung cancer with duodenal metastasis complicated by obstructive jaundice and pancreatitis: a case report.","authors":"Jie Kuang, Yanan Chen, Huikang Xie, Hua Hao, Yanlin Zhao, Cui Tang","doi":"10.3389/fonc.2025.1632696","DOIUrl":"10.3389/fonc.2025.1632696","url":null,"abstract":"<p><strong>Background: </strong>Primary lung adenocarcinoma with duodenal metastasis is relatively rare, and its early clinical symptoms are often insidious, making diagnosis challenging. CT, MR, PET-CT, and gastroscopy can effectively identify gastrointestinal metastatic lesions, providing reliable evidence for definitive diagnosis and treatment planning, which contributes to prolonging patient survival.</p><p><strong>Case presentation: </strong>This report presents a rare case of duodenal metastasis from lung adenocarcinoma. The patient was diagnosed with lung adenocarcinoma (cT4N3M1c, stage IVb) one year prior. During chemotherapy, the patient gradually developed symptoms of abdominal distension and progressive jaundice. Through analysis of CT and MR imaging changes during the disease course, combined with laboratory test indicators, malignant duodenal tumor causing biliary obstruction and pancreatitis was suspected. Ultimately, endoscopic pathological biopsy confirmed duodenal metastasis from primary lung cancer. The clinical surgeon implemented a PTCD treatment plan, successfully relieving the patient's biliary obstruction.</p><p><strong>Conclusions: </strong>Primary lung cancer patients presenting with abdominal symptoms and imaging findings suggestive of gastrointestinal tumors should be highly suspected of metastasis. Timely pathological diagnosis is essential to determine the nature and origin of the tumor, thereby facilitating the formulation of individualized treatment plans.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1632696"},"PeriodicalIF":3.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of brain necrosis and secondary cancers after proton beam therapy for pediatric intracranial tumors: a single-center retrospective study.","authors":"Masashi Mizumoto, Hiroko Fukushima, Yoshiko Oshiro, Takashi Saito, Ai Muroi, Yuni Yamaki, Sho Hosaka, Masako Inaba, Toshitaka Ishiguro, Masahiko Harada, Hikaru Niitsu, Toshiki Ishida, Taisuke Sumiya, Keiichiro Baba, Masatoshi Nakamura, Haruko Numajiri, Kei Nakai, Hideyuki Sakurai","doi":"10.3389/fonc.2025.1644839","DOIUrl":"10.3389/fonc.2025.1644839","url":null,"abstract":"<p><strong>Background: </strong>Proton beam therapy (PBT) is increasingly used for pediatric intracranial tumors due to lower long-term radiation-associated toxicities. However, data on late adverse effects, particularly brain necrosis and intracranial secondary cancer, remain limited. The aim of this study is to evaluate the incidence of these events following PBT in pediatric patients treated at a single center.</p><p><strong>Procedure: </strong>We retrospectively reviewed the medical records of 189 patients under 20 years of age who received PBT for intracranial tumors between 1991 and 2023. Clinical information, irradiation parameters, concurrent chemotherapy, and follow-up outcomes were collected. Brain necrosis and intracranial secondary cancers were assessed based on events presenting with grade ≥2 clinical symptoms.</p><p><strong>Results: </strong>Among 151 patients with sufficient follow-up data (median follow-up: 41.7 months), two cases of brain necrosis (1.3%) and two cases of intracranial secondary cancer (1.3%) were identified. The 5-year cumulative incidence was 2.3% (95% CI: 0-5.4%) for brain necrosis and 2.7% (95% CI: 0-6.4%) for intracranial secondary cancer. These respective incidence rates were similar for patients followed for more than two years (n=94), and slightly higher at 2.7% and 3.1% for those receiving a total dose >50 Gy (n=134). Among patients treated with PBT alone (n=125), the incidence was 1.7% for brain necrosis and 3.6% for secondary malignancy.</p><p><strong>Conclusions: </strong>This single-center retrospective study shows a low incidence of brain necrosis and secondary malignancy following PBT for pediatric patients with intracranial tumors. These findings indicate a favorable long-term safety profile of PBT in this population.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1644839"},"PeriodicalIF":3.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of immunotherapy in advanced non-small cell lung cancer with hypertension: a multicenter retrospective analysis.","authors":"Jingyi Yuan, Kaixin Lei, Quanling Kong, Tao Chang, Xinhang Gu, Juan Wang, Li-Na He, Jiadi Gan, Bojiang Chen","doi":"10.3389/fonc.2025.1621363","DOIUrl":"10.3389/fonc.2025.1621363","url":null,"abstract":"<p><strong>Importance: </strong>Immune checkpoint inhibitors (ICIs) have become the standard treatment for advanced non-small cell lung cancer (NSCLC). However, their prognostic role in NSCLC patients remains controversial. Hypertension (HTN) is an important risk factor for many cancers, but the pathogenesis underlying HTN in relation to cancer prognosis remains unclear.</p><p><strong>Objective: </strong>We aimed to investigate the possible association between HTN and prognosis in advanced NSCLC patients.</p><p><strong>Data sources: </strong>Data on advanced NSCLC patients receiving immunotherapy at stages IIIb, IIIc or IV were included.</p><p><strong>Study selection: </strong>Multicenter retrospective studies and trials reporting the use of immunotherapy were included. Main outcomes and measures: Progression-free survival (PFS) and overall survival (OS) were analyzed using Cox proportional hazards models and were estimated by the Kaplan-Meier method. Subgroup analysis on NSCLC hypertensive patients was pre-planned and was presented in the form of Forest Plot. Statistical software utilized for all analyses included statistical analysis system (SAS) V.9.4 and R version 4.2.2 (R Foundation for Statistical Computing).</p><p><strong>Results: </strong>Between January 2016 and June 2024, 1175 NSCLC patients receiving immunotherapy were enrolled, with 219 (18.6%) classified as hypertensive group and 956 (81.4%) classified as non-hypertensive group. Neutrophil count and ECOG = 2 showed a significant association with OS in univariate analysis (HR = 0.69, 95%Cl: 0.51 - 0.92, P = 0.012, and HR = 1.02, 95%Cl: 1.00 to 1.03, P = 0.008 respectively). In multivariate analysis, ECOG = 2 was significantly correlated with OS (HR = 0.73, 95%Cl: 0.54 to 0.98, P = 0.037) and PD - 1/PD-L1 had significant association with PFS (HR = 1.27, 95%Cl: 1.00 to 1.61, P = 0.050). OS was found significantly longer in non-hypertensive group than in hypertensive group (P = 0.049). No baseline indicator was found significant correlated with the survival prognosis of patients receiving immunotherapy in subgroup analysis.</p><p><strong>Conclusion and relevance: </strong>The non-hypertensive group was associated with a lower risk of mortality than hypertensive group. In subgroup analysis, no baseline indicator was observed a significant correlation with survival prognosis on OS and PFS in hypertensive patients. Our findings provided an important prognostic factor to improve the prognosis of advanced NSCLC patients receiving immunotherapy. Prospective randomized trials are needed to further validate these findings.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1621363"},"PeriodicalIF":3.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.","authors":"Yun Xu, Baoliang Zhong, Chunlin Yu, Qingjian Hou, Wenying Chen, Wen Zheng, Wenxiong Zhang, Tonggang Zhou","doi":"10.3389/fonc.2025.1590017","DOIUrl":"10.3389/fonc.2025.1590017","url":null,"abstract":"<p><strong>Background: </strong>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p><p><strong>Methods: </strong>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.</p><p><strong>Results: </strong>After screening, 19 phase 3 RCTs involving 9335 patients were included. Our updated analysis confirmed at PC therapy significantly improves OS (hazard ratio [HR]: 0.73 [0.69, 0.77], P < 0.00001), PFS (HR: 0.56 [0.52, 0.60], P < 0.00001), duration of response (DOR, HR: 0.50 [0.45, 0.54], P < 0.00001) and objective response rate (ORR, risk ratio [RR]: 1.59 [1.51, 1.67], P < 0.00001) compared to chemotherapy alone. The survival benefits were consistent across all subgroups and increases with longer follow-up. Brain metastases and PD-L1 combined positive score (CPS) > 50% were the favorable factors for PC group. However, the combined treatment was associated with an increased incidence of total/grade 3-5 treatment emergent AEs (TEAEs), and immune-related AEs (irAEs), although the overall safety profile remained manageable. The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p><p><strong>Conclusion: </strong>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. However, its higher incidence of AEs, especially irAEs, needs to be taken seriously.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251005925, identifier CRD420251005925.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1590017"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck cancer - emerging targeted therapies.","authors":"Yasser Abouelkheer, Aarti Bhatia","doi":"10.3389/fonc.2025.1640960","DOIUrl":"10.3389/fonc.2025.1640960","url":null,"abstract":"<p><p>Systemic therapy remains the cornerstone of treatment for recurrent and metastatic (R/M) head and neck squamous cell cancers (HNSCC). However, there is a dearth of effective treatments beyond platinum combinations, anti-programmed death-1 (PD-1) agents and the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab. Recent years have seen several exciting new agents being tested in clinical trials. These are designed to target alternate oncogenic signaling pathways and have novel mechanistic compositions, including bi-specific antibodies and antibody-drug conjugates. This review will delve into the clinical limitations of currently approved systemic therapies, explore newer agents in development and highlight ongoing clinical trials using targeted therapies in this disease.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1640960"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer.","authors":"Xiaokun Li, ZhuangZhuang Cong, Yong Qiang","doi":"10.3389/fonc.2025.1688480","DOIUrl":"10.3389/fonc.2025.1688480","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1688480"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of HER2-low and HER2-zero status on pathologic complete response and survival in triple-negative breast cancer: a meta-analysis.","authors":"Yu Qin, Chenchen Pu, Yuping Fan, Kepeng Zhu","doi":"10.3389/fonc.2025.1631125","DOIUrl":"10.3389/fonc.2025.1631125","url":null,"abstract":"<p><strong>Objective: </strong>To delve into the influence of different status of human epidermal growth factor receptor 2 (HER2) on the long-term survival of patients suffering from triple-negative breast cancer (TNBC), as well as the pathological complete response (pCR) following neoadjuvant therapy (NAT) via meta-analysis.</p><p><strong>Methods: </strong>A computer search in the Embase, PubMed, Web of Science, and Cochrane Library databases was executed up to January 13, 2025, to collect studies related to HER2 status in TNBC patients. The articles were screened per the inclusion and exclusion criteria. The required data were extracted. The study quality was appraised by means of the Newcastle-Ottawa Scale, and statistical analysis was carried out utilizing Stata 15.0 software.</p><p><strong>Results: </strong>36 studies involving 54,277 patients with TNBC were included. According to the meta-analysis, the pCR rate after NAT was more notable in the HER2-zero group compared to the HER2-low group (<i>RR</i> = 0.90, 95%<i>CI</i>: 0.86-0.93, <i>P <</i> 0.001). Regarding overall survival (OS), HER2-low patients exhibited a better prognosis (<i>HR</i> = 0.93, 95%<i>CI</i>: 0.90-0.97, <i>P</i> < 0.001). For disease-free survival, breast cancer-specific survival, and recurrence-free survival, HER2-low patients might experience an enhanced prognosis. However, the results did not exhibit statistically significant. The sensitivity analysis confirmed the robustness of the meta-analysis results. No publication bias existed in studies on each outcome indicator.</p><p><strong>Conclusion: </strong>HER2 status is essential for the prognostic assessment of TNBC patients, particularly in predicting pCR and OS outcomes.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier PROSPERO CRD-420250642369.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1631125"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}